WO2018123906A1 - 外用組成物 - Google Patents

外用組成物 Download PDF

Info

Publication number
WO2018123906A1
WO2018123906A1 PCT/JP2017/046238 JP2017046238W WO2018123906A1 WO 2018123906 A1 WO2018123906 A1 WO 2018123906A1 JP 2017046238 W JP2017046238 W JP 2017046238W WO 2018123906 A1 WO2018123906 A1 WO 2018123906A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
external use
mass
present
loxoprofen
Prior art date
Application number
PCT/JP2017/046238
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
岡本　浩明
Original Assignee
小林製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 小林製薬株式会社 filed Critical 小林製薬株式会社
Priority to CN201780080086.5A priority Critical patent/CN110099683B/zh
Publication of WO2018123906A1 publication Critical patent/WO2018123906A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a composition for external use.
  • Loxoprofen and its pharmaceutically acceptable salts which are propionic non-steroidal antipyretic analgesic / anti-inflammatory agents (NSAIDs) (in the present specification, these may be collectively referred to as “loxoprofen”) and others. Like the NSAID, it has antipyretic, analgesic and anti-inflammatory effects based on the inhibitory action of prostaglandin biosynthesis.
  • NSAIDs propionic non-steroidal antipyretic analgesic / anti-inflammatory agents
  • Patent Document 1 Various external preparations in which loxoprofen is blended as an active ingredient for antipyretic, analgesic and / or anti-inflammatory action have been developed (Patent Document 1). Various external preparations in which diclofenac, which is also NSAID, is further combined with a warming component have been proposed (Patent Document 2).
  • Patent Document 1 describes a composition for external use in which diclofenac is combined with capsaicinoid or the like as a warming component.
  • the inventor uses loxoprofen in combination with capsaicinoid or the like as a warming component, and uses alcohol having 1 to 4 carbon atoms as a solvent (in the present specification, these are sometimes collectively referred to as “lower alcohol”). It was found that the composition for external use has a tendency to brown over time.
  • An object of the present invention is to provide a composition for external use in which browning over time is suppressed.
  • the present inventor has intensively studied to solve the above-mentioned problems. As a result, by blending the lower alcohol to be contained in an amount of 55% by mass or more based on the whole composition, browning with time can be suppressed. I found it.
  • the present invention has been completed by further studies based on such findings, and includes the following aspects.
  • composition for external use (I-1) A composition comprising loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid, and an alcohol having 1 to 4 carbon atoms, wherein the alcohol is added to the whole composition The composition for external use which contains 55 mass% or more with respect to. (I-2) The composition for external use according to (I-1), wherein the capsaicinoid is nonanoic acid vanillylamide. (I-3) The composition for external use according to (I-1) or (I-2), further comprising an ester derivative of nicotinic acid. (I-4) The composition for external use according to any one of (I-1) to (I-3), which is used for analgesia. (I-5) The composition for external use according to any one of (I-1) to (I-4), which is a liquid agent.
  • composition containing loxoprofen or a pharmaceutically acceptable salt thereof, a capsaicinoid, and an alcohol having 1 to 4 carbon atoms in which browning with time is suppressed.
  • the external composition of the present invention is a composition containing loxoprofen or a pharmaceutically acceptable salt thereof (loxoprofen), capsaicinoid, and an alcohol having 1 to 4 carbon atoms.
  • the alcohol is contained in an amount of 55% by mass or more based on the entire composition.
  • composition for external use of the present invention contains loxoprofen as an active ingredient having at least one action selected from the group consisting of antipyretic, analgesic and anti-inflammatory actions.
  • Loxoprofen (2- [4- (2-oxocyclopentylmethyl) phenyl] propionic acid) is a propionic acid-based nonsteroidal antipyretic analgesic / antiinflammatory agent (NSAID) having antipyretic, analgesic and anti-inflammatory effects.
  • NSAID nonsteroidal antipyretic analgesic / antiinflammatory agent
  • salts thereof in addition to loxoprofen itself, pharmaceutically acceptable salts thereof can also be used.
  • Such salts include solvates of loxoprofen or a pharmaceutically acceptable salt thereof with water or alcohol. These are known compounds, which can be produced by known methods, and commercially available products can also be used.
  • loxoprofen sodium hydrate is preferred as loxoprofen or a pharmaceutically acceptable salt thereof.
  • the content of loxoprofen is not particularly limited as long as it is an effective effective amount.
  • the content is, for example, 0.1 to 10% by mass, preferably 0.5 to 5% by mass, more preferably 0.5 to 3%, in terms of loxoprofen sodium anhydride, based on the total composition for external use of the present invention. It can be made into the mass%.
  • composition for external use of the present invention contains capsaicinoid as an active ingredient for warming action.
  • N-acyl vanillylamide can be used as capsaicinoid.
  • N-acyl vanillylamide is a known compound as a blood circulation promoter.
  • the acyl group in N-acyl vanillyl amide may be either linear or branched. Further, the carbon number of the acyl group in N-acyl vanillyl amide is not particularly limited, and may be, for example, 5 to 15, preferably 6 to 11.
  • N-acyl vanillyl amide examples include nonanoic acid vanillyl amide and capsaicins such as capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin and homodihydrocapsaicin.
  • a refined product may be used as the capsaicinoid, but a mixture containing other components in addition to capsaicinoid may be used.
  • a mixture containing capsaicinoid include peppers such as pepper extract, pepper tincture, and pepper powder.
  • capsaicinoid one kind of capsaicinoid may be used alone, or two or more kinds may be used in combination.
  • capsaicinoids nonanoic acid vanillylamide is preferable from the viewpoint that it is easier to exhibit the effect of suppressing browning with time by combining with ethanol.
  • the content of capsaicinoid in the present invention is not particularly limited as long as it is effective in terms of efficacy.
  • the content can be, for example, 0.002 to 0.2% by mass with respect to the entire external composition of the present invention, and preferably 0.003 to 0.05 from the viewpoint of the effect of suppressing browning over time.
  • the amount can be set to mass%, more preferably 0.01 to 0.015 mass%.
  • the ratio of capsainoside can also be set in consideration of the ratio to loxoprofen contained in the composition for external use.
  • the ratio of capsainoside is usually in the range of 0.002 to 0.2 parts by mass with respect to 1 part by mass of loxoprofens contained in the composition for external use, preferably 0.003 to 0.05 parts by mass, more preferably 0.01 to 0.015 parts by mass.
  • composition for external use of the present invention can further contain an nicotinic acid ester derivative as an active ingredient for warming action.
  • ADVANTAGE OF THE INVENTION According to this invention, even if it contains the ester derivative of nicotinic acid, the composition for external use which has the outstanding property can be obtained, without producing further browning.
  • the composition for external use of the present invention further contains an ester derivative of nicotinic acid, thereby further enhancing the effect of suppressing browning over time.
  • the ester derivative of nicotinic acid is not particularly limited as long as it is pharmaceutically acceptable, and can be used widely. Examples thereof include nicotinic acid benzyl ester, nicotinic acid ⁇ -butoxyethyl ester and nicotinic acid methyl ester. These ester derivatives of nicotinic acid may be used alone or in combination of two or more. Of the ester derivatives of nicotinic acid, nicotinic acid benzyl ester is preferred.
  • the content of the ester derivative of nicotinic acid in the present invention is not particularly limited as long as it is effective in terms of efficacy.
  • the content can be, for example, 0.002 to 0.2% by mass with respect to the entire external composition of the present invention, and preferably 0.003 to 0.05 from the viewpoint of the effect of suppressing browning over time.
  • the amount can be set to mass%, more preferably 0.008 to 0.015 mass%.
  • the ratio of the ester derivative of nicotinic acid can also be set in consideration of the ratio to loxoprofen contained in the composition for external use.
  • the ratio of the ester derivative of nicotinic acid is usually in the range of 0.002 to 0.2 parts by mass with respect to 1 part by mass of loxoprofens contained in the composition for external use, preferably The amount is 0.003 to 0.05 parts by mass, more preferably 0.008 to 0.015 parts by mass.
  • C1-C4 alcohol lower alcohol
  • the lower alcohol is not particularly limited and can be widely used as long as it functions as an effective base for the above active ingredients.
  • the lower alcohol examples include methanol, ethanol, propyl alcohol and isopropyl alcohol, with ethanol being preferred.
  • the external composition of the present invention contains 55% by mass or more of a lower alcohol with respect to the entire composition. Thereby, the composition for external use of the present invention is one in which browning with time is suppressed.
  • the external composition of the present invention preferably contains 90% by mass or less, more preferably 80% by mass or less, of the lower alcohol with respect to the entire composition.
  • composition for external use of the present invention preferably contains 60% by mass or more of a lower alcohol with respect to the entire composition from the viewpoint of the effect of suppressing browning over time.
  • the composition for external use of the present invention contains 55 to 90% by mass of the lower alcohol with respect to the whole composition, thereby suppressing the skin browning over time while suppressing the skin irritation.
  • the lower alcohol is preferably contained in an amount of 60 to 90% by mass, more preferably 60 to 80% by mass, based on the entire composition.
  • a refreshing agent in the composition for external use of the present invention, can be blended in addition to the above components as long as the effects of the present invention are not hindered.
  • Such refreshing agents include l-menthol, d-menthol, dl-menthol, d-camphor, dl-camphor, d-borneol, dl-borneol, menthane, menthol lactate, geraniol, eucalyptus oil, terpene oil, bergamot oil , Fennel oil, peppermint oil (peppermint), rose oil, cool mint and the like. These cooling agents may be used alone or in any combination of two or more.
  • the refreshing agent contained in the composition for external use of the present invention is preferably l-menthol, d-menthol, dl-menthol, d-borneol, dl-borneol, menthane, peppermint oil (peppermint) and cool mint, Menthol is more preferable, and l-menthol is particularly preferable.
  • a medicinal aid in the composition for external use of the present invention, can be blended in addition to the above components as long as the effects of the present invention are not hindered.
  • Such pharmaceutical adjuvants include anti-inflammatory agents and skin protectants such as glycyrrhetinic acid, dipotassium glycyrrhizinate, ammonium glycyrrhizinate, stearyl glycyrrhizinate; diphenylimidazole, diphenhydramine and pharmaceutically acceptable salts thereof, chlorpheny maleate,
  • skin protectants such as glycyrrhetinic acid, dipotassium glycyrrhizinate, ammonium glycyrrhizinate, stearyl glycyrrhizinate; diphenylimidazole, diphenhydramine and pharmaceutically acceptable salts thereof, chlorpheny maleate
  • antihistamines such as lamin
  • blood circulation promoters such as tocopherol acetate
  • herbal medicines such as arnica tincture, agaric extract, sushi extract, horse chestnut extract, funnel extract, bella
  • composition for external use of the present invention in addition to the above-mentioned components, active ingredients that can be used in combination, pH adjusters, preservatives, preservatives, antioxidants, stabilizers, etc., which are used for usual external compositions
  • An agent can be appropriately blended.
  • composition for external use of the present invention is not particularly limited in form, but is preferably a liquid (including lotions, sprays, aerosols, and emulsions).
  • composition for external use of the present invention can be prepared according to a conventional method depending on the form of the preparation.
  • loxoprofen, capsainoside, or, if necessary, an ester derivative of nicotinic acid mixed with a general-purpose base used in external preparations as described below, including lower alcohols, dissolved or dispersed The method of adjusting to pH can be mentioned.
  • the pH is not limited as long as it does not adversely affect the skin, and is usually adjusted to pH 3.5 to 8.5, preferably pH 4 to 8, more preferably 4 to 7.5.
  • composition for external use of the present invention when the composition for external use of the present invention is prepared as a liquid, by mixing loxoprofen, capsainoside, and, if necessary, an ester derivative of nicotinic acid with a base mainly composed of a lower alcohol.
  • a base mainly composed of a lower alcohol.
  • the base at least one selected from glycols, water and an emulsifier can be blended.
  • glycols are not particularly limited, and examples include glycerin, propylene glycol, 1,3-butylene glycol, octanediol, ethylene glycol, polyethylene glycol, D-sorbitol and the like. Glycerin, propylene glycol and 1,3-butylene glycol are preferred.
  • a glycol may be used individually by 1 type and may be used in combination of multiple types.
  • the emulsifier is not particularly limited, and examples thereof include nonionic surfactants such as sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyl stearate, and lauromacrogol.
  • An emulsifier may be used individually by 1 type and may be used in combination of multiple types.
  • the external composition of the present invention is preferably prepared as an external preparation in the form of a coating and can be locally administered externally.
  • the dosage of the composition for external use of the present invention depends on the degree of the symptom to be treated. However, the dosage per day of loxoprofen, which is an active ingredient contained therein, is 100 mg or less. It is desirable to be.
  • composition for external use of the present invention is a topical anti-inflammatory analgesic, such as shoulder pain associated with stiff shoulders, joint pain, low back pain, muscle pain, tendonitis (hand / wrist pain), elbow pain (tennis elbow etc.), bruise pain, It can be suitably used for the purpose of analgesia against pains such as pain, fractures, and neuralgia.
  • analgesic such as shoulder pain associated with stiff shoulders, joint pain, low back pain, muscle pain, tendonitis (hand / wrist pain), elbow pain (tennis elbow etc.), bruise pain
  • the method of the present invention comprises a composition comprising loxoprofen or a pharmaceutically acceptable salt thereof, capsaicinoid and an alcohol having 1 to 4 carbon atoms. In which the content ratio of the alcohol to the entire composition is 55% by mass or more.
  • Each component to be blended in such a composition including loxoprofen and capsaicinoid, is as described for the external composition of the present invention of (I) above.
  • the step of setting the content ratio of the alcohol to the entire composition to 55% by mass or more is not particularly limited, and may be performed by mixing each component as described for the external composition of the present invention of (I) above. it can.
  • the order of mixing is not particularly limited.
  • an embodiment in which the effect can be exhibited to a higher degree is an embodiment in which an ester derivative of nicotinic acid is further added to the composition in addition to loxoprofen and capsaicinoid.
  • the unit represents mass (g) (that is, mass%) per 100 g of the composition.
  • each component was weighed and weighed, and a liquid composition was prepared by stirring and dissolving (Examples 1 to 6, Comparative Examples 1 to 4).
  • FIG. 1 shows photographs of “ ⁇ ” and “ ⁇ ”. The left side is a photograph of “ ⁇ ” (Example 1) and the right side is “ ⁇ ” (Comparative Example 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2017/046238 2016-12-27 2017-12-22 外用組成物 WO2018123906A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780080086.5A CN110099683B (zh) 2016-12-27 2017-12-22 外用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016254186A JP6847656B2 (ja) 2016-12-27 2016-12-27 外用組成物
JP2016-254186 2016-12-27

Publications (1)

Publication Number Publication Date
WO2018123906A1 true WO2018123906A1 (ja) 2018-07-05

Family

ID=62707413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/046238 WO2018123906A1 (ja) 2016-12-27 2017-12-22 外用組成物

Country Status (4)

Country Link
JP (1) JP6847656B2 (zh)
CN (1) CN110099683B (zh)
TW (1) TWI788316B (zh)
WO (1) WO2018123906A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020059666A (ja) * 2018-10-09 2020-04-16 小林製薬株式会社 外用医薬組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020045315A (ja) * 2018-09-20 2020-03-26 興和株式会社 ロキソプロフェンを含有する医薬製剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014002599A1 (ja) * 2012-06-25 2014-01-03 興和株式会社 生薬等含有医薬組成物
JP2014172857A (ja) * 2013-03-08 2014-09-22 Lion Corp 外用組成物
JP2015027971A (ja) * 2013-07-31 2015-02-12 興和株式会社 ロキソプロフェン含有外用塗布剤
JP2015193540A (ja) * 2013-03-29 2015-11-05 興和株式会社 ロキソプロフェン含有外用固形剤
WO2017111167A1 (ja) * 2015-12-25 2017-06-29 興和株式会社 ロキソプロフェンを含有する医薬製剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014002599A1 (ja) * 2012-06-25 2014-01-03 興和株式会社 生薬等含有医薬組成物
JP2014172857A (ja) * 2013-03-08 2014-09-22 Lion Corp 外用組成物
JP2015193540A (ja) * 2013-03-29 2015-11-05 興和株式会社 ロキソプロフェン含有外用固形剤
JP2015027971A (ja) * 2013-07-31 2015-02-12 興和株式会社 ロキソプロフェン含有外用塗布剤
WO2017111167A1 (ja) * 2015-12-25 2017-06-29 興和株式会社 ロキソプロフェンを含有する医薬製剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020059666A (ja) * 2018-10-09 2020-04-16 小林製薬株式会社 外用医薬組成物
JP7226957B2 (ja) 2018-10-09 2023-02-21 小林製薬株式会社 外用医薬組成物

Also Published As

Publication number Publication date
CN110099683A (zh) 2019-08-06
JP6847656B2 (ja) 2021-03-24
TWI788316B (zh) 2023-01-01
TW201827046A (zh) 2018-08-01
JP2018104368A (ja) 2018-07-05
CN110099683B (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
JP5590846B2 (ja) 外用医薬組成物
WO2018123906A1 (ja) 外用組成物
JP2024037972A (ja) 外用製剤
JP2022176219A (ja) 外用製剤
JP6900189B2 (ja) 外用組成物
JP7412871B2 (ja) 外用組成物
JP7086597B2 (ja) 外用組成物
JP7234268B2 (ja) 外用組成物
JP7412870B2 (ja) 外用組成物
JP7086596B2 (ja) 外用組成物
JP7206042B2 (ja) 外用組成物
JP7206043B2 (ja) 外用組成物
JP7098320B2 (ja) 外用組成物
JP5832602B2 (ja) 外用医薬組成物
JP7164976B2 (ja) 外用医薬組成物
JP7186025B2 (ja) 外用医薬組成物
JP7229678B2 (ja) 外用医薬組成物
JP7156825B2 (ja) 外用医薬組成物
JP5565995B2 (ja) 鎮痒剤
WO2022270200A1 (ja) 水性外用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17888268

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17888268

Country of ref document: EP

Kind code of ref document: A1